image by: Medication - MHML

HWN Suggests

The Jakafi Report

This is by no means a scientifically controlled study. The results were derived from an MPNforum Magazine on-line request for first hand responses from the early adopters of Jakafi. This qualitative study supplements scientific reports with fresh testimony from the patient pioneers in this revolutionary MF treatment. (Jakafi is the first drug approved by the FDA and EHA to treat myelofibrosis therapeutically and the drug that clinically demonstrated the efficacy of kinase inhibition.)

read full article

Resources

 The Jakafi Report

In an anecdotal survey of 21 MPN patients taking Jakafi for relief of MF symptoms, first results vary from highly positive to unacceptable.

ChemoCare

For the treatment of intermediate and high risk myelofibrosis. For the treatment of acute graft-versus-host (GVHD) not responsive steroids, in adults and pediatric patients 12 years of older.

Jakafi

For the treatment of intermediate and high risk myelofibrosis. For the treatment of acute graft-versus-host (GVHD) not responsive steroids, in adults and pediatric patients 12 years of older.

GoodRx

Jakafi (Ruxolitinib) is an expensive drug that targets proteins in cells and stops them from growing. It is used to treat myelofibrosis and polycythemia vera. It is slightly more popular than comparable drugs.

OncoLink

Ruxolitinib is a type of targeted therapy called a kinase inhibitor. A kinase is an enzyme that promotes cell growth. There are many types of kinases, which control different phases of cell growth. By blocking a particular enzyme from working, this medication can slow the growth of cancer cells. Ruxolitinib targets Janus Associated Kinases, JAK1, and JAK2.